Table 2

Baseline characteristics of study subjects included in the intention to treat analyses

Self-management (n=98)Usual care (n=95)p value
Figures are mean (SD) values unless stated otherwise.
FEV1=forced expiratory volume in 1 second in litres; FVC=forced vital capacity.
*Missing data (self-management 2; usual care 1); **missing data (self-management 2; usual care 2); †pretreatment consisted of 6 weeks budesonide 800 μg twice daily; ‡difference between FEV1 before and after bronchodilator/predicted FEV1.
Age (years)39.6 (11.2)39.3 (12.0)0.859
Sex (M/F)34/6440/560.394
Smoking:
    Never smokers45 (46%)54 (56%)
    Former smokers31 (32%)21 (22%)
    Current smokers22 (22%)21 (22%)0.254
    Pack years*5.8 (4.5)5.7 (4.5)0.881
Requiring pretreatment with budesonide†34 (35%)22 (23%)0.077
% with asthma attack(s) in previous 6 months48.5%31.6%0.017
FEV1 (% predicted value):
    Pre-bronchodilator (BD)**84.0 (13.1)86.9 (14.2)0.141
    Post-bronchodilator (BD)90.0 (12.1)92.6 (12.9)0.135
FEV1 reversibility (%) (median)‡ **
    PostBD – preBD/predicted5.0 (8.6) IQR5.4 (6.8) IQR0.930
Bronchial hyperresponsiveness
    PC20 geometric mean1.200.970.442
Initial dose of inhaled steroids0.622
    None12 (12%)16 (17%)
    Low (<400 μg daily or equivalent)36 (37%)30 (32%)
    Intermediate (≥400 and <800 μg daily or equivalent)34 (35%)37 (39%)
    High (≥800 μg daily or equivalent)16 (16%)12 (12%)
Quality of life:
    Activities domain5.3 (1.03)5.6 (0.77)0.015
    Emotions domain5.8 (1.01)6.2 (0.76)0.002
    Symptoms domain5.3 (1.03)5.6 (0.90)0.074
    Environment domain5.3 (1.10)5.5 (1.1)0.165
    Overall score5.4 (0.872)5.7 (0.771)0.013